EchoGen Emulsion which uses PhaseShift technology to convert liquid emulsion into gas microbubbles in the bloodstream data

The Bothell, Wash., company announced Phase II results in 59 patients, showing significantly increased visualization of blood flow and tumors.

The contrast agent showed a sensitivity of 96 percent and a specificity of 93 percent. The number of patients who were found to have lesions was significantly increased (p=0.046), with a changed diagnosis for 12 percent of the patients. ...